AML Molecular Panel

The AML Molecular Panel is a comprehensive molecular diagnostic test used to identify important genetic alterations associated with Acute Myeloid Leukemia (AML). It evaluates multiple clinically significant gene mutations and chromosomal rearrangements, including PML-RARA, BCR-ABL, AML1-ETO, INV(16), FLT3, NPM1, and C-KIT. These genetic markers help characterize the disease at a molecular level, supporting accurate diagnosis, disease classification, risk assessment, and treatment planning. The test is an important component of personalized care for individuals with suspected or confirmed AML.

Who Should Get This Test Done?

This test may be recommended for individuals who:

●      Have been diagnosed with or are suspected of having Acute Myeloid Leukemia (AML).

●      Need molecular profiling to support the diagnosis and classification of AML.

●      Require genetic testing before starting targeted or personalized treatment.

●      Are undergoing evaluation for prognosis and risk stratification of leukemia.

●      Need molecular monitoring as part of their ongoing AML management, as advised by a hematologist or oncologist.

Why Consider This Test?

Acute Myeloid Leukemia can develop due to a variety of genetic changes, and identifying these abnormalities is essential for understanding the disease. The AML Molecular Panel detects several clinically relevant mutations and gene rearrangements that help healthcare providers classify AML more accurately and determine the most appropriate treatment approach. It also provides valuable information for risk assessment and follow-up. By combining multiple molecular markers in a single panel, the test offers a detailed genetic profile that supports informed clinical decision-making.

More Information

The AML Molecular Panel evaluates a range of molecular abnormalities commonly associated with Acute Myeloid Leukemia, including fusion genes and mutations that may influence disease behavior and therapeutic choices. It is typically performed on blood or bone marrow samples, depending on the clinical indication. The results are interpreted alongside bone marrow examination, immunophenotyping, cytogenetic analysis, and other laboratory findings to provide a comprehensive evaluation of the disease and guide individualized patient care.

Other Names

The Molecular Panel AML test may also be referred to as:

●      AML Molecular Markers Panel

●      Acute Myeloid Leukemia Genetic Panel

●      AML Mutation Panel

●      Myeloid Leukemia Fusion Gene Panel

●      AML Chromosomal Abnormality Panel

●      AML Next Generation Sequencing Panel

●      Myeloid Neoplasm Molecular Panel